
Microbiology & Infectious Diseases
16 Oct 2025
EACS 2025: Low Risk of HBV Reactivation After Tenofovir Withdrawal in People With HIV
Late-breaking data at EACS 2025 show a very low rate of hepatitis B reactivation in people with HIV who stopped tenofovir, with all HBV DNA levels below quantification, supporting the safety of tenofovir-sparing antiretroviral therapy strategies.
Latest Journals
All JournalsCongress Reviews
All Congress ReviewsLatest Infographics
All InfographicsLatest Podcasts
All Podcasts